Alebund Pharmaceuticals (Jiangsu) Limited (HKG:9637)
Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
28.80
+0.30 (1.05%)
At close: Sep 4, 2026

HKG:9637 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
122.630.566.53
Revenue Growth
-368.29%-
Cost of Revenue
23.3317.114.14
Gross Profit
99.2713.452.39
Selling, General & Admin
318.4287.6377.28
Research & Development
403.92372.57235.37
Operating Expenses
722.32660.21312.65
Operating Income
-623.05-646.76-310.27
Interest Expense
-49.81-110.55-29.38
Interest & Investment Income
3.411.430.57
Earnings From Equity Investments
-37.39-2.820
Currency Exchange Gain (Loss)
-4.83-0.130.05
Other Non Operating Income (Expenses)
5.955.153.89
EBT Excluding Unusual Items
-705.71-753.67-335.13
Gain (Loss) on Sale of Investments
1.11.95-
Gain (Loss) on Sale of Assets
-0.1-0.1-0
Pretax Income
-704.71-751.82-335.13
Earnings From Continuing Operations
-704.71-751.82-335.13
Minority Interest in Earnings
0.91.789.1
Net Income
-703.81-750.04-326.03
Net Income to Common
-703.81-750.04-326.03
Net Income Growth
---
Shares Outstanding (Basic)
272244272
Shares Outstanding (Diluted)
272244272
Shares Change
--10.08%-
EPS (Basic)
-2.58-3.07-1.20
EPS (Diluted)
-2.58-3.07-1.20
EPS Growth
---

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
Free Cash Flow
--389.51-480.52
Free Cash Flow Per Share
--1.59-1.77
Gross Margin
80.97%44.00%36.55%
Operating Margin
-508.18%-2116.64%-4755.03%
Profit Margin
-574.05%-2454.63%-4996.57%
Free Cash Flow Margin
--1274.74%-7364.34%
EBITDA
-567.15-607.19-303.36
D&A For EBITDA
55.939.576.91
EBIT
-623.05-646.76-310.27